ALX Oncology (NASDAQ:ALXO) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research report report published on Wednesday,Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, ALX Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

ALX Oncology Price Performance

Shares of NASDAQ ALXO traded down $0.19 during trading on Wednesday, reaching $1.65. The company had a trading volume of 798,310 shares, compared to its average volume of 815,373. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The stock has a 50-day moving average price of $1.49 and a two-hundred day moving average price of $3.39. The stock has a market capitalization of $87.03 million, a PE ratio of -0.55 and a beta of 1.04.

Insider Transactions at ALX Oncology

In related news, Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was purchased at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 33.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Barclays PLC increased its stake in ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after acquiring an additional 42,185 shares during the last quarter. XTX Topco Ltd purchased a new position in ALX Oncology in the third quarter valued at approximately $578,000. Wellington Management Group LLP lifted its position in ALX Oncology by 15.2% during the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after buying an additional 22,114 shares in the last quarter. Verition Fund Management LLC lifted its position in ALX Oncology by 308.4% during the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock valued at $242,000 after buying an additional 100,454 shares in the last quarter. Finally, Walleye Capital LLC grew its stake in ALX Oncology by 110.3% during the third quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after buying an additional 121,113 shares during the period. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.